SCHEMBL6081184

SCHEMBL6081184

CSc1ccc(CNC(=O)c2ccnc(N[C@@H](C)c3ccccc3)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.45
HTR7 P34969 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
ADORA1 P30542 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPK1 P28482 1/20 0.42
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
EPHX2 P34913 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6081771 0.85 MAPK8 (0.46) MAPK14HTR7MEN1KMT2AMAPK1
SCHEMBL6081494 0.84 MAPK14 (0.44) MAPK14HTR7ADORA3ADORA2AADORA2B
SCHEMBL4644151 0.80 RAB9A (0.45) HTR7MEN1KMT2AALDH1A1KDM4E
SCHEMBL6081327 0.80 MAPK14 (0.52) MAPK14HTR7ADORA3ADORA2AADORA2B
SCHEMBL6081490 0.78 MAPK14 (0.50) MAPK14HTR7EPHX2HDAC3HDAC1
SCHEMBL6082367 0.78 MAPK14 (0.50) MAPK14HTR7EPHX2HDAC3HDAC1
SCHEMBL6081738 0.78 MAPK14 (0.49) MAPK14HTR7EPHX2HDAC3HDAC1
SCHEMBL20187393 0.76 MAPK14 (0.56) MAPK14HTR7KDM4EHDAC3HDAC1
SCHEMBL30123472 0.76 MAPK14 (0.56) MAPK14HTR7KDM4EHDAC3HDAC1
SCHEMBL6081874 0.76 MAPK14 (0.47) MAPK14HTR7KDM4EHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060199821-A1 Heterocyclic amides and sulfonamides SCIOS, INC. (US) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199821-A1 Heterocyclic amides and sulfonamides MAP4K2, MAP3K8, MAP3K2 MAPK14 28/4885HTR7 1715/4885MEN1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.